Partnership Established to Provide Customers with Multi-Omics Data Access

PhenoVista Biosciences and Carolina Molecular announced a partnership to combine complementary CRO service capabilities to expand clients' access to broader multi-omic data. PhenoVista is a leading provider of cell-based testing services and specializes in high-content imaging and analysis, including downstream machine learning and subsequent quantitative biology.

The partnership with Carolina Molecular enables joint customers to complement functional and phenotypic cellular data with orthogonal molecular readouts, including robust immunoassay technologies or RNA sequencing to identify important protein markers and gene expression analysis using targeted qPCR tests, as well as broader transcriptomic profiling. By combining Carolina Molecular's molecular testing services with PhenoVista's high-content imaging expertise, customers will have access to high-quality, multi-omic data to inform drug discovery timelines.

James Evans, Chief Executive Officer and co-founder of PhenoVista, said, "As industry trends continue to shift toward increased outsourcing, the need for more relevant biological testing in human cells and tissues, and the need for more complex datasets combined with machine learning, PhenoVista is proud to be positioned not only to meet these customer expectations but hopefully to exceed them."

John L. Corliss, co-founder of Carolina Molecular, said, "Carolina Molecular is excited to combine forces with PhenoVista to bring together our full-spectrum clinical and discovery expertise to deliver high-quality, data-driven solutions advancing therapeutic innovations for both scientists and patients." Through this new partnership, combining Carolina Molecular's state-of-the-art profiling technologies with PhenoVista's unique expertise in developing cell-based, high-content, imaging-based tests, PhenoVista and Carolina Molecular customers will gain a broader and deeper understanding of drug candidates.

Source